JP2018522887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522887A5 JP2018522887A5 JP2018501155A JP2018501155A JP2018522887A5 JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5 JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018501155 A JP2018501155 A JP 2018501155A JP 2018522887 A5 JP2018522887 A5 JP 2018522887A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- hpv
- subject
- antibody according
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022169277A JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562192396P | 2015-07-14 | 2015-07-14 | |
| US62/192,396 | 2015-07-14 | ||
| PCT/US2016/042297 WO2017011666A1 (en) | 2015-07-14 | 2016-07-14 | Method of treating cancer using immune checkpoint inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Division JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018522887A JP2018522887A (ja) | 2018-08-16 |
| JP2018522887A5 true JP2018522887A5 (enExample) | 2019-08-22 |
Family
ID=56551000
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018501155A Withdrawn JP2018522887A (ja) | 2015-07-14 | 2016-07-14 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022169277A Pending JP2023024973A (ja) | 2015-07-14 | 2022-10-21 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
| JP2025106098A Pending JP2025138726A (ja) | 2015-07-14 | 2025-06-24 | 免疫チェックポイント阻害剤を使用する癌の処置法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10544224B2 (enExample) |
| EP (3) | EP3858859B1 (enExample) |
| JP (3) | JP2018522887A (enExample) |
| KR (2) | KR20180027576A (enExample) |
| CN (1) | CN107922502A (enExample) |
| CY (1) | CY1123993T1 (enExample) |
| DK (2) | DK3322731T3 (enExample) |
| ES (2) | ES3055227T3 (enExample) |
| FI (1) | FI3858859T3 (enExample) |
| HR (2) | HRP20251434T1 (enExample) |
| HU (1) | HUE053966T2 (enExample) |
| LT (2) | LT3322731T (enExample) |
| PL (1) | PL3322731T3 (enExample) |
| PT (2) | PT3858859T (enExample) |
| RS (2) | RS67652B1 (enExample) |
| SI (2) | SI3858859T1 (enExample) |
| SM (2) | SMT202600008T1 (enExample) |
| WO (1) | WO2017011666A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| CA2986765A1 (en) | 2015-05-29 | 2016-12-08 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| HK1254954A1 (zh) | 2015-06-29 | 2019-08-02 | Biomed Valley Discoveries, Inc. | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 |
| CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
| SI3858859T1 (sl) | 2015-07-14 | 2026-03-31 | Bristol-Myers Squibb Company | Postopek zdravljenja raka z uporabo zaviralca imunskih kontrolnih točk; protitelo, ki se veže na receptor programirane celične smrti-1 (pd-1) ali ligand programirane celične smrti 1 (pd-l1) |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| EP3344656A1 (en) | 2015-09-01 | 2018-07-11 | Agenus Inc. | Anti-pd-1 antibodies and methods of use thereof |
| CN108350081A (zh) * | 2015-11-18 | 2018-07-31 | 百时美施贵宝公司 | 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌 |
| RU2018125603A (ru) * | 2015-12-17 | 2020-01-21 | Новартис Аг | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения |
| WO2017157882A1 (en) | 2016-03-14 | 2017-09-21 | Université Catholique de Louvain | Serine biosynthetic pathway inhibitors |
| JP7373991B2 (ja) * | 2016-07-15 | 2023-11-06 | ビラクタ セラピューティクス，インク． | 免疫療法で使用するためのヒストン脱アセチル化酵素阻害剤 |
| WO2018065938A1 (en) * | 2016-10-06 | 2018-04-12 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| FI3551660T3 (fi) | 2016-12-07 | 2023-12-11 | Agenus Inc | Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä |
| CN118634323A (zh) | 2016-12-07 | 2024-09-13 | 艾吉纳斯公司 | 抗体和其使用方法 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| US11701433B2 (en) * | 2017-06-05 | 2023-07-18 | The Regents Of The University Of Michigan | Complexes for delivery of antigenic peptides |
| JP7402164B2 (ja) * | 2018-01-12 | 2023-12-20 | グレイル エルエルシー | ウイルス核酸を解析する方法 |
| CN119792515A (zh) * | 2018-02-13 | 2025-04-11 | 默沙东有限责任公司 | 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法 |
| WO2019175328A1 (en) | 2018-03-14 | 2019-09-19 | Imba - Institut Für Molekulare Biotechnologie Gmbh | Bh4pathwayactivationandusethereoffortreatingcancer |
| KR20200139724A (ko) * | 2018-03-30 | 2020-12-14 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| EP3801501A4 (en) | 2018-06-06 | 2022-03-23 | The Regents of the University of California | ESTROGEN RECEPTOR INHIBITORS AND THEIR USES |
| US20210255168A1 (en) * | 2018-06-13 | 2021-08-19 | King Faisal Specialist Hospital & Research Centre | A method of precision cancer therapy |
| BR112021008117A2 (pt) * | 2018-10-31 | 2021-08-31 | Genentech, Inc. | Método e medicamento para tratamento de câncer que não responde ao inibidor de sinalização pd-1/pd-l1 |
| WO2020156500A1 (zh) * | 2019-01-31 | 2020-08-06 | 正大天晴药业集团股份有限公司 | 抗pd-l1抗体治疗头颈癌的用途 |
| DE102019208563B4 (de) | 2019-06-12 | 2026-03-26 | Volkswagen Aktiengesellschaft | Optischer Flüssigkeitssensor und elektrisches System zur optischen Detektion von Flüssigkeiten |
| EP4074338A4 (en) * | 2019-12-13 | 2024-03-06 | Samsung Bioepis Co., Ltd. | PHARMACEUTICAL PREPARATION OF STABLE ANTI-PD-1 ANTIBODY |
| EP4076521A4 (en) * | 2019-12-20 | 2024-01-24 | Merck Sharp & Dohme LLC | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| KR102541413B1 (ko) | 2020-02-06 | 2023-06-12 | 영남대학교 산학협력단 | 면역 체크포인트 억제제 및 ampk 활성화제를 유효성분으로 함유하는 암질환 예방 또는 치료용 조성물 |
| GB2629999B (en) * | 2021-04-21 | 2025-03-26 | Act Therapeutics Ltd | Enhancement of treatment with immunotherapeutic agents |
| KR102779377B1 (ko) | 2022-07-22 | 2025-03-12 | 가톨릭대학교 산학협력단 | 디옥시시코닌 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
| KR102893442B1 (ko) * | 2022-12-23 | 2025-12-01 | 가톨릭대학교 산학협력단 | 켈레리트린 클로라이드 또는 그의 약제학적으로 허용가능한 염을 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| IL132240A0 (en) | 1997-04-07 | 2001-03-19 | Genentech Inc | Anti-vegf antibodies |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
| CN102766210B (zh) | 1999-08-24 | 2015-07-08 | E.R.施贵宝&圣斯有限责任公司 | 人ctla-4抗体及其应用 |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| US7498414B2 (en) | 2002-03-04 | 2009-03-03 | Imclone Systems Incorporated | Human antibodies specific to KDR and uses thereof |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| DK1819358T3 (da) | 2004-11-18 | 2014-10-27 | Imclone Llc | Antistoffer mod vaskulær endothel-vækstfaktor-receptor-1 |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| KR101510065B1 (ko) * | 2005-06-08 | 2015-04-07 | 다나-파버 캔서 인스티튜트 인크. | 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물 |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| WO2012122444A1 (en) | 2011-03-10 | 2012-09-13 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| SI2699264T1 (en) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| LT2904011T (lt) | 2012-10-02 | 2017-11-10 | Bristol-Myers Squibb Company | Anti-kir antikūnų ir anti-pd-1 antikūnų derinys, akirtas vėžio gydymui |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| AU2014323523B2 (en) * | 2013-09-20 | 2020-02-20 | Bristol-Myers Squibb Company | Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors |
| CA2935423C (en) * | 2014-01-24 | 2023-11-07 | Dana-Farber Cancer Institute, Inc. | Antibody molecules to pd-1 and uses thereof |
| US20160031990A1 (en) | 2014-05-29 | 2016-02-04 | Medlmmune, Llc | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| US10354541B2 (en) | 2014-07-02 | 2019-07-16 | Raytheon Bbn Technologies Corporation | Tutor model building system |
| MA40344A (fr) * | 2014-07-18 | 2016-01-21 | Advaxis Inc | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer |
| US20170247455A1 (en) | 2014-08-22 | 2017-08-31 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| MY188749A (en) * | 2015-04-17 | 2021-12-28 | Bristol Myers Squibb Co | Compositions comprising a combination of nivolumab and ipilimumab |
| SI3858859T1 (sl) | 2015-07-14 | 2026-03-31 | Bristol-Myers Squibb Company | Postopek zdravljenja raka z uporabo zaviralca imunskih kontrolnih točk; protitelo, ki se veže na receptor programirane celične smrti-1 (pd-1) ali ligand programirane celične smrti 1 (pd-l1) |
-
2016
- 2016-07-14 SI SI201631932T patent/SI3858859T1/sl unknown
- 2016-07-14 EP EP20214749.2A patent/EP3858859B1/en active Active
- 2016-07-14 KR KR1020187003984A patent/KR20180027576A/ko not_active Ceased
- 2016-07-14 DK DK16744626.9T patent/DK3322731T3/da active
- 2016-07-14 JP JP2018501155A patent/JP2018522887A/ja not_active Withdrawn
- 2016-07-14 KR KR1020257014642A patent/KR20250065936A/ko active Pending
- 2016-07-14 EP EP25203723.9A patent/EP4679094A3/en active Pending
- 2016-07-14 HU HUE16744626A patent/HUE053966T2/hu unknown
- 2016-07-14 DK DK20214749.2T patent/DK3858859T3/da active
- 2016-07-14 HR HRP20251434TT patent/HRP20251434T1/hr unknown
- 2016-07-14 FI FIEP20214749.2T patent/FI3858859T3/fi active
- 2016-07-14 LT LTEP16744626.9T patent/LT3322731T/lt unknown
- 2016-07-14 SM SM20260008T patent/SMT202600008T1/it unknown
- 2016-07-14 EP EP16744626.9A patent/EP3322731B1/en not_active Revoked
- 2016-07-14 ES ES20214749T patent/ES3055227T3/es active Active
- 2016-07-14 LT LTEP20214749.2T patent/LT3858859T/lt unknown
- 2016-07-14 PT PT202147492T patent/PT3858859T/pt unknown
- 2016-07-14 US US15/210,612 patent/US10544224B2/en active Active
- 2016-07-14 PT PT167446269T patent/PT3322731T/pt unknown
- 2016-07-14 WO PCT/US2016/042297 patent/WO2017011666A1/en not_active Ceased
- 2016-07-14 PL PL16744626T patent/PL3322731T3/pl unknown
- 2016-07-14 CN CN201680052756.8A patent/CN107922502A/zh active Pending
- 2016-07-14 RS RS20251179A patent/RS67652B1/sr unknown
- 2016-07-14 SI SI201631090T patent/SI3322731T1/sl unknown
- 2016-07-14 ES ES16744626T patent/ES2855798T3/es active Active
- 2016-07-14 HR HRP20210399TT patent/HRP20210399T1/hr unknown
- 2016-07-14 SM SM20210131T patent/SMT202100131T1/it unknown
- 2016-07-14 RS RS20210284A patent/RS61532B1/sr unknown
-
2019
- 2019-12-05 US US16/704,913 patent/US20200190198A1/en not_active Abandoned
-
2021
- 2021-03-26 CY CY20211100264T patent/CY1123993T1/el unknown
-
2022
- 2022-10-21 JP JP2022169277A patent/JP2023024973A/ja active Pending
-
2023
- 2023-07-26 US US18/359,696 patent/US20240124592A1/en active Pending
-
2025
- 2025-06-24 JP JP2025106098A patent/JP2025138726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210399T1 (hr) | Postupak liječenja raka primjenom inhibitora imunološke kontrolne točke; antitijelo koje se vezuje za receptor programirane smrti-1 (pd-1) ili ligand programirane smrti-1 (pd-l1) | |
| JP2018515474A5 (enExample) | ||
| Hude et al. | The emerging role of immune checkpoint inhibition in malignant lymphoma | |
| JP2018514550A5 (enExample) | ||
| KR102333658B1 (ko) | 비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체 | |
| MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
| IL278423B1 (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
| JP2019503387A5 (enExample) | ||
| JP2018500332A5 (enExample) | ||
| Vici et al. | Emerging biological treatments for uterine cervical carcinoma | |
| JP2016528195A5 (enExample) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| MX2024000780A (es) | Anticuerpo anti-pd-1 para usarse en el tratamiento de cancer de pulmon. | |
| MX2022014867A (es) | Anticuerpos especificos del receptor de poliovirus humano (rvp). | |
| JP2016525117A5 (enExample) | ||
| CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
| JP2017534633A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| JP2017537090A5 (enExample) | ||
| JP2017524715A5 (enExample) | ||
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| JP2019517498A5 (enExample) | ||
| JP2022500410A5 (enExample) | ||
| JP2023525664A (ja) | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト | |
| JP2019517504A5 (enExample) |